The GSDMD Knockout KYSE-150 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human esophageal squamous cell carcinoma KYSE-150 cell line, with targeted disruption of the GSDMD gene. This heterogeneous cell pool enables loss-of-function studies without clonal selection, minimizing clonal bias and providing a genetically diverse background for functional assays. This product format mitigates variability inherent in monoclonal lines.
The KYSE-150 cell line originates from a well-differentiated human esophageal squamous cell carcinoma and serves as a robust model for esophageal cancer biology, drug response testing, and tumor microenvironment studies. The adherent epithelial cells maintain key oncogenic pathways, making them suitable for dissecting cancer cell death mechanisms and inflammatory signaling.
GSDMD is the central executor of pyroptosis, a lytic programmed cell death pathway. Upon activation of the NLRP3 inflammasome by stimuli such as ATP or bacterial LPS, the adaptor ASC recruits and activates CASP1, which proteolytically cleaves GSDMD. Additionally, cytosolic LPS triggers non-canonical inflammasome signaling via CASP4 and CASP5, which also cleave GSDMD. The released N-terminal domain of GSDMD oligomerizes in the plasma membrane, forming pores that permeabilize the cell and cause the release of pro-inflammatory cytokines IL?1?? and IL?18, the danger signal HMGB1, and cytosolic enzymes like LDH. Key interacting partners include CASP1, CASP4, CASP5, NLRP3, and ASC (PYCARD). This pathway converges on the NOD-like receptor signaling cascade, positioning GSDMD as a critical mediator of innate immune responses and inflammatory cell death.
In esophageal squamous cell carcinoma, pyroptosis and GSDMD functionality are increasingly recognized for their roles in tumor cell fate, immune cell recruitment, and therapeutic response. The GSDMD knockout KYSE-150 polyclonal cells provide a context-specific system to investigate how disruption of pyroptotic execution alters cancer cell viability, cytokine secretion profiles, migration behavior, and sensitivity to chemotherapeutic or pyroptosis-inducing agents. Such studies can illuminate the dual role of pyroptosis in tumor suppression and promotion, and aid in identifying druggable nodes within the GSDMD signaling axis.
These polyclonal knockout cells are tailored for detailed investigations into pyroptosis mechanisms, inflammasome regulation, and inflammatory cell death pathways. Typical assays include LDH release measurement to assess membrane damage, IL?1?? and IL?18 ELISA for cytokine quantification, Western blotting to monitor GSDMD cleavage and caspase activation, propidium iodide uptake for membrane permeability, and cell viability or migration assays to determine functional outcomes. The model supports drug sensitivity screening with NLRP3 activators, LPS/ATP treatments, and can be paired with wild-type controls to delineate GSDMD-dependent effects in esophageal cancer context. For additional information and technical support, please contact Ascent Research.
